Amedisys Inc (AMED) 28.62 $AMED
Amedisys Chief Medical Officer, Michael Fleming, MD, FAAFP, States We Can Do Right by Patients at End of Life
GlobeNewswire - Thu Feb 12, 9:00AM CST
A new study about end-of-life care may be only about half right, asserts Michael Fleming, MD, FAAFP and chief medical officer for Amedisys Inc. (Nasdaq:AMED), a national leader in healthcare at home and hospice. http://medicaring.org/2015/02/02/symptom-prevalence/
AMED: 28.62 (+0.16)
Critical Alerts For Interxion, Amedisys, 3M, Medivation and Dominos Pizza Released By InvestorsObserver
PR Newswire - Thu Feb 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for INXN, AMED, MMM, MDVN and DPZ.
MDVN: 104.71 (+0.67), MMM: 165.94 (+0.03), DPZ: 100.00 (-0.56), INXN: 32.04 (+0.14), AMED: 28.62 (+0.16)
What One Ought to Know in the Healthcare Sector: New Research on Amarin, Amedica, Amedisys, American CareSource, and AS&E
PR Newswire - Thu Feb 12, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
ANCI: 3.10 (-0.20), AMRN: 1.18 (unch), ASEI: 56.82 (+0.30), AMED: 28.62 (+0.16), AMDA: 0.65 (+0.01)
Uptrend Call Working As Amedisys Stock Rises 75.4% (AMED)
Comtex SmarTrend(R) - Mon Feb 09, 10:58AM CST
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on June 27th, 2014 at $16.01. In approximately 8 months, Amedisys has returned 75.45% as of today's recent price of $28.08.
AMED: 28.62 (+0.16)
Commit To Buy Amedisys At $24, Earn 12.4% Annualized Using Options
at The Street - Mon Feb 09, 10:33AM CST
Investors eyeing a purchase of Amedisys, Inc. stock, but tentative about paying the going market price of $28.12/share, might benefit from considering selling puts among the alternative strategies at their disposal.
AMED: 28.62 (+0.16)
Anthem Shares Fall Post Huge Data Breach, China Suspected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 1:27PM CST
After a series of data breaches at major U.S. companies over the past two years it is now health insurer Anthem Inc. (ANTM) which has been struck.
ANTM: 141.05 (-0.95), UNH: 109.44 (-0.40), AMED: 28.62 (+0.16), HLS: 45.01 (+0.30)
Quest Diagnostics Strong on Earnings, Long-Term Prospects - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 10:32AM CST
On Feb 5, 2015, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
USPH: 41.08 (+0.07), DGX: 71.68 (+0.03), AMED: 28.62 (+0.16), HLS: 45.01 (+0.30)
Quest Diagnostics Q4 Earnings, Revenues Beat; Grow Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 2:37PM CST
Quest Diagnostics' (DGX) fourth-quarter 2014 adjusted earnings per share (EPS) from continuing operations of $1.08 exceeded the Zacks Consensus Estimate by 3 cents.
AMSG: 55.56 (+0.48), RDNT: 8.66 (-0.11), DGX: 71.68 (+0.03), AMED: 28.62 (+0.16)
79.6% Return Seen to Date on SmarTrend Amedisys Call (AMED)
Comtex SmarTrend(R) - Mon Jan 26, 9:09AM CST
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on June 27th, 2014 at $16.01. In approximately 7 months, Amedisys has returned 79.63% as of today's recent price of $28.75.
AMED: 28.62 (+0.16)
How Useful Is the PEG Ratio?
Anders Bylund, The Motley Fool - Motley Fool - Fri Jan 23, 7:00PM CST
The PEG ratio is a useful shorthand for stock valuation. You get it by dividing a stock's current price-to-earnings ratio by its earnings growth rate. You want the number to be low, but not negative. Master investor Peter Lynch loves this tool....
WCC: 68.20 (+1.34), PL: 69.95 (-0.01), JACK: 87.12 (-1.00), ESL: 115.76 (+0.80), CHE: 107.38 (-0.43), DECK: 77.08 (+0.61), SBH: 33.10 (+0.28), CRI: 83.65 (+0.52), AMED: 28.62 (+0.16), BKE: 49.59 (-0.16)
DaVita's Inorganic Growth Initiatives Look Impressive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 16, 3:10PM CST
On Jan 16, we issued an updated research report on DaVita HealthCare Partners Inc. (DVA).
ACC: 43.30 (-0.25), DVA: 73.10 (-3.29), AMED: 28.62 (+0.16), HLS: 45.01 (+0.30)
Pricing OK this year for Amedisys
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 3:49PM CST
AMED: 28.62 (+0.16)
Amedisys Updates Impact of 2015 Medicare Home Health Prospective Payment System Final Rule
GlobeNewswire - Thu Jan 15, 12:45PM CST
Amedisys, Inc. (Nasdaq:AMED), one of America's leading home health and hospice care companies, today announced that it expects the impact of the 2015 Medicare Home Health Prospective Payment System Final Rule to be more moderate than previously anticipated. Previously, the company had disclosed that it expected an impact of -0.80% relative to 2014 Medicare pricing; however, after further analysis, the company now expects the 2015 pricing to be relatively unchanged from 2014.
AMED: 28.62 (+0.16)
Amedisys is Looking for Tuck-ins in the Wake of Its Restructuring
at The Street - Thu Jan 15, 7:41AM CST
However, new CEO says larger deals may be on the horizon for the home healthcare services provider.
AMED: 28.62 (+0.16)
Is Quest Diagnostics (DGX) Worth Adding to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 3:50PM CST
On Jan 13, Zacks Investment Research upgraded Quest Diagnostics Inc. (DGX) to a Zacks Rank #1 (Strong Buy).
PMC: 24.40 (-0.18), DGX: 71.68 (+0.03), AMED: 28.62 (+0.16), GTIV: 19.19 (-0.23)
Anthem's M&A Ventures, Capital Activities Impress; Costs Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 1:20PM CST
On Jan 12, 2014, we issued an updated research report on Anthem Inc. (ANTM), earlier known as WellPoint Inc.
CNC: 118.18 (-0.01), ANTM: 141.05 (-0.95), UNH: 109.44 (-0.40), AMED: 28.62 (+0.16)
Amedisys Has Returned 80.7% Since SmarTrend Recommendation (AMED)
Comtex SmarTrend(R) - Fri Jan 09, 11:00AM CST
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on June 27th, 2014 at $16.01. In approximately 7 months, Amedisys has returned 80.69% as of today's recent price of $28.92.
AMED: 28.62 (+0.16)
Amedisys to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Thu Jan 08, 10:00AM CST
Amedisys, Inc. (Nasdaq:AMED), one of America's leading home health and hospice care companies, today announced that Paul B. Kusserow, President and Chief Executive Officer, Ronald A. LaBorde, Vice Chairman, and Dale E. Redman, Interim Chief Financial Officer, will present at the 33 Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2015.
JPM: 59.67 (+0.10), AMED: 28.62 (+0.16)
Amedisys Chief Medical Officer, Michael Fleming, MD, FAAFP, States We Can Do Right by Patients at End of Life
GlobeNewswire - Thu Feb 12, 9:00AM CST
A new study about end-of-life care may be only about half right, asserts Michael Fleming, MD, FAAFP and chief medical officer for Amedisys Inc. (Nasdaq:AMED), a national leader in healthcare at home and hospice. http://medicaring.org/2015/02/02/symptom-prevalence/
AMED: 28.62 (+0.16)
Critical Alerts For Interxion, Amedisys, 3M, Medivation and Dominos Pizza Released By InvestorsObserver
PR Newswire - Thu Feb 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for INXN, AMED, MMM, MDVN and DPZ.
MDVN: 104.71 (+0.67), MMM: 165.94 (+0.03), DPZ: 100.00 (-0.56), INXN: 32.04 (+0.14), AMED: 28.62 (+0.16)
What One Ought to Know in the Healthcare Sector: New Research on Amarin, Amedica, Amedisys, American CareSource, and AS&E
PR Newswire - Thu Feb 12, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
ANCI: 3.10 (-0.20), AMRN: 1.18 (unch), ASEI: 56.82 (+0.30), AMED: 28.62 (+0.16), AMDA: 0.65 (+0.01)
Uptrend Call Working As Amedisys Stock Rises 75.4% (AMED)
Comtex SmarTrend(R) - Mon Feb 09, 10:58AM CST
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on June 27th, 2014 at $16.01. In approximately 8 months, Amedisys has returned 75.45% as of today's recent price of $28.08.
AMED: 28.62 (+0.16)
Commit To Buy Amedisys At $24, Earn 12.4% Annualized Using Options
at The Street - Mon Feb 09, 10:33AM CST
Investors eyeing a purchase of Amedisys, Inc. stock, but tentative about paying the going market price of $28.12/share, might benefit from considering selling puts among the alternative strategies at their disposal.
AMED: 28.62 (+0.16)
Anthem Shares Fall Post Huge Data Breach, China Suspected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 1:27PM CST
After a series of data breaches at major U.S. companies over the past two years it is now health insurer Anthem Inc. (ANTM) which has been struck.
ANTM: 141.05 (-0.95), UNH: 109.44 (-0.40), AMED: 28.62 (+0.16), HLS: 45.01 (+0.30)
Quest Diagnostics Strong on Earnings, Long-Term Prospects - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 10:32AM CST
On Feb 5, 2015, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
USPH: 41.08 (+0.07), DGX: 71.68 (+0.03), AMED: 28.62 (+0.16), HLS: 45.01 (+0.30)
Quest Diagnostics Q4 Earnings, Revenues Beat; Grow Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 2:37PM CST
Quest Diagnostics' (DGX) fourth-quarter 2014 adjusted earnings per share (EPS) from continuing operations of $1.08 exceeded the Zacks Consensus Estimate by 3 cents.
AMSG: 55.56 (+0.48), RDNT: 8.66 (-0.11), DGX: 71.68 (+0.03), AMED: 28.62 (+0.16)
79.6% Return Seen to Date on SmarTrend Amedisys Call (AMED)
Comtex SmarTrend(R) - Mon Jan 26, 9:09AM CST
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on June 27th, 2014 at $16.01. In approximately 7 months, Amedisys has returned 79.63% as of today's recent price of $28.75.
AMED: 28.62 (+0.16)
How Useful Is the PEG Ratio?
Anders Bylund, The Motley Fool - Motley Fool - Fri Jan 23, 7:00PM CST
The PEG ratio is a useful shorthand for stock valuation. You get it by dividing a stock's current price-to-earnings ratio by its earnings growth rate. You want the number to be low, but not negative. Master investor Peter Lynch loves this tool....
WCC: 68.20 (+1.34), PL: 69.95 (-0.01), JACK: 87.12 (-1.00), ESL: 115.76 (+0.80), CHE: 107.38 (-0.43), DECK: 77.08 (+0.61), SBH: 33.10 (+0.28), CRI: 83.65 (+0.52), AMED: 28.62 (+0.16), BKE: 49.59 (-0.16)
DaVita's Inorganic Growth Initiatives Look Impressive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 16, 3:10PM CST
On Jan 16, we issued an updated research report on DaVita HealthCare Partners Inc. (DVA).
ACC: 43.30 (-0.25), DVA: 73.10 (-3.29), AMED: 28.62 (+0.16), HLS: 45.01 (+0.30)
Pricing OK this year for Amedisys
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 3:49PM CST
AMED: 28.62 (+0.16)
Amedisys Updates Impact of 2015 Medicare Home Health Prospective Payment System Final Rule
GlobeNewswire - Thu Jan 15, 12:45PM CST
Amedisys, Inc. (Nasdaq:AMED), one of America's leading home health and hospice care companies, today announced that it expects the impact of the 2015 Medicare Home Health Prospective Payment System Final Rule to be more moderate than previously anticipated. Previously, the company had disclosed that it expected an impact of -0.80% relative to 2014 Medicare pricing; however, after further analysis, the company now expects the 2015 pricing to be relatively unchanged from 2014.
AMED: 28.62 (+0.16)
Amedisys is Looking for Tuck-ins in the Wake of Its Restructuring
at The Street - Thu Jan 15, 7:41AM CST
However, new CEO says larger deals may be on the horizon for the home healthcare services provider.
AMED: 28.62 (+0.16)
Is Quest Diagnostics (DGX) Worth Adding to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 3:50PM CST
On Jan 13, Zacks Investment Research upgraded Quest Diagnostics Inc. (DGX) to a Zacks Rank #1 (Strong Buy).
PMC: 24.40 (-0.18), DGX: 71.68 (+0.03), AMED: 28.62 (+0.16), GTIV: 19.19 (-0.23)
Anthem's M&A Ventures, Capital Activities Impress; Costs Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 1:20PM CST
On Jan 12, 2014, we issued an updated research report on Anthem Inc. (ANTM), earlier known as WellPoint Inc.
CNC: 118.18 (-0.01), ANTM: 141.05 (-0.95), UNH: 109.44 (-0.40), AMED: 28.62 (+0.16)
Amedisys Has Returned 80.7% Since SmarTrend Recommendation (AMED)
Comtex SmarTrend(R) - Fri Jan 09, 11:00AM CST
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on June 27th, 2014 at $16.01. In approximately 7 months, Amedisys has returned 80.69% as of today's recent price of $28.92.
AMED: 28.62 (+0.16)
Amedisys to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Thu Jan 08, 10:00AM CST
Amedisys, Inc. (Nasdaq:AMED), one of America's leading home health and hospice care companies, today announced that Paul B. Kusserow, President and Chief Executive Officer, Ronald A. LaBorde, Vice Chairman, and Dale E. Redman, Interim Chief Financial Officer, will present at the 33 Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2015.
JPM: 59.67 (+0.10), AMED: 28.62 (+0.16)
